Literature DB >> 159020

D-penicillamine and immune complex deposition.

J D Kirby, P A Dieppe, E C Huskisson, B Smith.   

Abstract

Dense, granular immunoglobulin deposits have been identified at the epidermo-dermal junction in 4 out of 10 patients who developed toxic reactions to D-penicillamine therapy for rheumatoid arthritis. Three of 4 patients developing a lupus-like syndrome while on penicillamine had similar findings on skin biopsy. Serum immunoglobulin and complement levels decreased significantly in patients treated with penicillamine. It is suggested that, in addition to penicillamine nephropathy, other side effects of this drug may be related to widespread deposition of immune complexes.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 159020      PMCID: PMC1000368          DOI: 10.1136/ard.38.4.344

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  10 in total

1.  Specific therapy for rheumatoid arthritis.

Authors:  E C Huskisson
Journal:  Rheumatol Rehabil       Date:  1976-08

2.  [100 cases of common rheumatoid polyarthritis, treated with D-penicillamin].

Authors:  J P Camus; J Crouzet; P Guillien; C Benichou; J A Lievre
Journal:  Ann Med Interne (Paris)       Date:  1974-01

Review 3.  The diagnosis of systemic lupus erythematosus.

Authors:  G R Hughes
Journal:  Br J Haematol       Date:  1973-10       Impact factor: 6.998

4.  Detection and radioassay of soluble circulating immune complexes using guinea pig peritoneal exudate cells.

Authors:  I I Onyewotu; E J Holborow; G D Johnson
Journal:  Nature       Date:  1974-03-08       Impact factor: 49.962

5.  Lupus-like syndrome induced by D-penicillamine in Wilson's disease.

Authors:  J P Harpey; B Caille; R Moulias; J M Goust
Journal:  Lancet       Date:  1971-02-06       Impact factor: 79.321

6.  Nephropathy induced by D-penicillamine.

Authors:  I A Jaffe; G Treser; Y Suzuki; T Ehrenreich
Journal:  Ann Intern Med       Date:  1968-09       Impact factor: 25.391

7.  Effect of D-penicillamine on serum immunoglobulins and rheumatoid factor.

Authors:  R Bluestone; L S Goldberg
Journal:  Ann Rheum Dis       Date:  1973-01       Impact factor: 19.103

8.  Effect of penicillamine therapy on circulating immune complexes in rheumatoid arthritis.

Authors:  I Mohammed; D Barraclough; E J Holborow; B M Ansell
Journal:  Ann Rheum Dis       Date:  1975-10       Impact factor: 19.103

9.  Penicillamine nephropathy in rheumatoid arthritis. A clinical, pathological and immunological study.

Authors:  P A Bacon; C R Tribe; J C Mackenzie; J Verrier-Jones; R H Cumming; B Amer
Journal:  Q J Med       Date:  1976-10

10.  Factors relating to circulating immune complexes in rheumatoid arthirits.

Authors:  P J Roberts-Thomson; B L Hazleman; I G Barnett; I C MacLennan; A G Mowat
Journal:  Ann Rheum Dis       Date:  1976-08       Impact factor: 19.103

  10 in total
  7 in total

1.  Immune deposits at the dermoepidermal junction in patients with rheumatoid arthritis.

Authors:  P A Brougham; P E McGill; J Tulloch
Journal:  Ann Rheum Dis       Date:  1984-06       Impact factor: 19.103

2.  [Goodpasture's syndrome--rapid remission after early plasmapheresis and high-dose cyclophosphamide therapy (author's transl)].

Authors:  H H Euler; L Kleine; H J Gutschmidt; J D Herrlinger
Journal:  Klin Wochenschr       Date:  1982-06-15

3.  Management of proteinuria secondary to penicillamine therapy in rheumatoid arthritis.

Authors:  R N DeSilva; C J Eastmond
Journal:  Clin Rheumatol       Date:  1992-06       Impact factor: 2.980

4.  Natural course of penicillamine nephropathy: a long term study of 33 patients.

Authors:  C L Hall; S Jawad; P R Harrison; J C MacKenzie; P A Bacon; P T Klouda; A G MacIver
Journal:  Br Med J (Clin Res Ed)       Date:  1988-04-16

5.  Progressive proliferative glomerulonephritis in a patient with rheumatoid arthritis treated with D-penicillamine.

Authors:  A J Williams; J N Fordham; C G Barnes; F J Goodwin
Journal:  Ann Rheum Dis       Date:  1986-01       Impact factor: 19.103

6.  Morphea-like reaction to D-penicillamine therapy.

Authors:  R M Bernstein; M A Hall; B E Gostelow
Journal:  Ann Rheum Dis       Date:  1981-02       Impact factor: 19.103

7.  Dermatomyositis induced by penicillamine.

Authors:  F Wojnarowska
Journal:  J R Soc Med       Date:  1980-12       Impact factor: 18.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.